Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Shares Shorted: Short Interest Down 36.0% in October

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the target of a significant drop in short interest in the month of October. As of October 15th, there was short interest totaling 8,701 shares, a drop of 36.0% from the September 30th total of 13,598 shares. Based on an average daily trading volume, of 35,468 shares, the short-interest ratio is currently 0.2 days. Currently, 0.7% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Aspire Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 25th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has an average rating of “Sell”.

Aspire Biopharma Price Performance

ASBP traded down $0.19 during trading hours on Monday, reaching $7.92. 3,928 shares of the stock traded hands, compared to its average volume of 266,134. The company has a market cap of $11.09 million, a price-to-earnings ratio of -0.11 and a beta of 0.17. Aspire Biopharma has a fifty-two week low of $3.31 and a fifty-two week high of $468.00. The firm’s fifty day simple moving average is $8.55 and its two-hundred day simple moving average is $17.94.

Aspire Biopharma Company Profile

Aspire Biopharma, Inc is a clinical-stage biopharmaceutical company developing orally administered therapies using a proprietary fast-dissolving tablet and sublingual delivery platform. The company’s technology is designed to deliver active ingredients through the tissues beneath the tongue, potentially allowing rapid absorption while reducing reliance on the gastrointestinal tract and first-pass metabolism.

Aspire’s lead development program has focused on an orally dissolvable epinephrine product intended for the emergency treatment of severe allergic reactions, including anaphylaxis.